MARKET

ALKS

ALKS

Alkermes
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.23
-0.05
-0.26%
After Hours: 19.23 0 0.00% 16:00 03/08 EST
OPEN
19.31
PREV CLOSE
19.28
HIGH
19.74
LOW
19.11
VOLUME
1.40M
TURNOVER
--
52 WEEK HIGH
23.92
52 WEEK LOW
11.98
MARKET CAP
3.06B
P/E (TTM)
-27.5304
1D
5D
1M
3M
1Y
5Y
--S&P Revises Alkermes Outlook to Stable From Negative; Ratings Affirmed
MT Newswires · 8h ago
Alkermes, Inc. -- Moody's assigns Ba3 to Alkermes' term loan; stable outlook
Rating Action: Moody's assigns Ba3 to Alkermes' term loan; stable outlookGlobal Credit Research - 08 Mar 2021New York, March 08, 2021 -- Moody's Investors Service ("Moody's") assigned a Ba3 rating to the new senior secured term loan of Alkermes, Inc., a su...
Moody's · 12h ago
Baudax Bio Strengthens Management Team with Appointment of Richard S. Casten as Chief Financial Officer
MALVERN Pa., March 08, Mar 08, 2021 (GLOBE NEWSWIRE via COMTEX) -- MALVERN Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a...
GlobeNewswire · 14h ago
Global Polymers Drug Delivery Market Size, Share, Value, and Competitive Landscape 2020-2026
Mar 06, 2021 (Heraldkeepers) -- Global Polymers Drug Delivery Market Report 2020 comes with the extensive industry analysis of development components,...
Heraldkeepers · 2d ago
Alkermes Provides Resources for Those Experiencing Substance Use Disorder and Isolation During the Pandemic
Mar 05, 2021 (3BL Media via COMTEX) -- SOURCE:AlkermesDESCRIPTION: Many people with Substance Use Disorder are struggling with isolation during the pandemic....
3BL Media · 3d ago
Alkermes to Hold Virtual Investor Day
Alkermes plc (Nasdaq: ALKS) announced today that it will hold a virtual Investor Day on Thursday, March 25, 2021, beginning at 9:00 a.m. ET (1:00 p.m. GMT). During the event, members of Alkermes' senior management and research and development team will dis...
PR Newswire · 4d ago
Drug Delivery Devices Market Worth Observing Growth: Nipro, Roche, Boehringer Ingelheim
Mar 01, 2021 (Market Insight Reports) -- Global Drug Delivery Devices Market Growth 2021-2026 is latest research study released by HTF MI evaluating the...
Market Insight Reports · 03/01 18:03
Opioid Use Disorder Market Size, Share, Growth, Industry Analysis, Opportunities and Forecast 2019-2025
Mar 01, 2021 (Market Insight Reports) -- The global opioid use disorder market is estimated to witness significant growth during the forecast period...
Market Insight Reports · 03/01 10:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALKS. Analyze the recent business situations of Alkermes through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALKS stock price target is 21.89 with a high estimate of 28.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 349
Institutional Holdings: 167.05M
% Owned: 104.90%
Shares Outstanding: 159.24M
TypeInstitutionsShares
Increased
69
9.24M
New
58
2.32M
Decreased
62
7.35M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.02%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Chief Executive Officer/Director
Richard Pops
Chief Financial Officer/Senior Vice President/Chief Accounting Officer
Iain Brown
Chief Operating Officer/Executive Vice President
Blair Jackson
Executive Vice President
Craig Hopkinson
Senior Vice President/Chief Compliance Officer/Secretary
David Gaffin
Senior Vice President/Chief Risk Officer
Michael Landine
Lead Director/Independent Director
David Anstice
Director
Shane Cooke
Independent Director
Robert Breyer
Independent Director
David Daglio
Independent Director
Wendy Dixon
Independent Director
Richard Gaynor
Independent Director
Brian McKeon
Independent Director
Paul Mitchell
Independent Director
Nancy Snyderman
Independent Director
Frank Wilson
Independent Director
Nancy Wysenski
No Data
  • All
  • Financials
  • Insiders
More
About ALKS
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Webull offers kinds of Alkermes Plc stock information, including NASDAQ:ALKS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALKS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALKS stock methods without spending real money on the virtual paper trading platform.